EMA Withdrawn: Rasilamlo (aliskiren;amlodipine) — Novartis Europharm Ltd

View source ↗

Summary

The EMA lists Rasilamlo (aliskiren and amlodipine) as withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Rasilamlo (aliskiren;amlodipine)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd. Decision date: 25/06/2015